As we draw towards the end of this millennium, it despite the majority of strokes occurring in the elderly population, and hypertension remaining a significant will become clear whether the aspirations raised by the Health of the Nation document will be realized risk factor in this age group, other factors become increasingly more important in older people. It has with regard to the reduction in mortality from stroke. The target of a 40% decrease in stroke deaths by the been estimated that for the population as a whole, 75% of strokes occur in the 90% of individuals with year 2000 in those aged 65-74 years may initially have appeared optimistic without any specific new a BP <155/95 mmHg.5 Hypertension type also affects stroke risk. In older age groups, isolated sysinterventions, but mortality rates have been consistently falling in both the UK and most, but not all, tolic hypertension (ISH) has a greater RR than diastolic hypertension (3.2 and 2.1 respectively) when Westernized countries over the past 2-3 decades.1 This decrease in mortality is probably due to a comcompared to normotensives, but this increased risk with ISH is reversed in those aged 40-59 years (7.7 bination of decreased stroke incidence and stroke severity, as well as a reduction in death rate following and 10.3, respectively).6 There has been much debate as to whether the the acute event. However, in the UK there are still over 120 000 strokes per annum, about 20% being relation between increasing BP levels and stroke is linear or J-shaped, particularly in older groups. due to a recurrence. Overall, 20% will die within the first few months of the event, and up to 35% of the MacMahon et al. 7 have convincingly demonstrated a log-linear correlation between cerebrovascular dissurvivors will still be dependent after a year.2 Primary stroke reduction must come from attacking the major ease risk and BP in younger age groups, and more recent studies have shown that the same holds true risk factors, of which hypertension remains the primary treatable cause. This editorial deals primarily with for the Á65 years age group.8,9 The apparent J-shaped curve seen in some studies is probably the relation between ischaemic stroke and blood pressure (BP), and the benefits or otherwise of BP related to co-morbidity at the time of BP measurement rather than from low BP per se. The relation reduction in both primary and secondary prevention.
Data from prospective observational studies have between BP and cardiovascular disease in the very elderly (Á75 years) is not as obvious as in younger highlighted the strong association between increasing BP levels and stroke incidence for both cerebral age groups, and an increasing body of evidence suggests that high levels may actually indicate a haemorrhage and infarction. In the Prospective Studies Collaboration, a meta-analysis of 45 studies favourable survival pattern.10 If it is unclear that hypertension in this very elderly group is a risk factor, involving 450 000 subjects aged 15-99 years with a mean follow-up of 16 years, diastolic blood pressure it is even more uncertain as to the benefits of treatment, and hopefully studies such as Hypertension in (DBP) levels were closely related to stroke risk after adjustment for other potential confounding variables; the Very Elderly Trial (HYVET) will answer this important question.11 for every 10 mmHg DBP increase, stroke risk rose by 80%.3 However the BP/stroke relation varies with Evidence continues to accumulate from intervention studies in both young and elderly hypertensives age, the gradient being much steeper in younger than in older age groups. In the Honolulu heart study, the of the benefits from pharmacological BP lowering.
Reducing levels by about 15/6 mmHg in younger relative risk (RR) of thromboembolic stroke associated with hypertension in 45-54-year-old males was 6.1 patients will decrease stroke incidence by nearly 50%, but this would only account for about 1-2 compared with 1.6 in the 65-81-year-olds.4 The attributable stroke risk due to hypertension similarly strokes avoided per 1000 patient-years of treatment.12 In older patients, for similar BP decreases, stroke risk decreases with age, with <20% of strokes in the Á65 years age group being related to elevated BP will be reduced by about 34%, cardiovascular deaths by 23% and the overall death rate by 10%, which levels, compared to 50% in 45-54 year olds.4 So means a reduction of up to 9 strokes per 1000 patientfactors of a poor stroke outcome, that for every 10 mmHg increase in 24-h SBP levels on admission, years of treatment (allowing for withdrawal biases) in older hypertensives.12 Patients with both combined the likelihood of death or severe disability at 30 days is almost doubled.24 However, this does not necessarhypertension (systolic and diastolic) and ISH appear to benefit from treatment to the same degree.13,14 The ily mean that lowering BP will be of benefit in the acute post-stroke period and the literature is littered most common first-line anti-hypertensive agents to date have been diuretics and beta-blockers, but more with reports of adverse effects of pharmacological reduction in the acute situation. It is even theoreticrecently the longer-acting dihydropyridine calcium channel blockers have also been shown to reduce ally possible that increasing BP in the acute stroke period may be of benefit, perhaps in those with signistroke incidence.14 Only when we have the results of ongoing studies comparing the older and newer ficant carotid stenosis.25 To date there have been no large, randomized trials of BP modification in the families of anti-hypertensive agents will we know whether the more recently introduced compounds acute stroke period, and these are much needed.
Currently there seems little evidence to suggest that provide any additional benefit. However, if we seriously wish to reduce stroke incidence, it is insuffipharmacologically altering BP acutely is of value, unless there are other pressing medical reasons, e.g. cient just to diagnose hypertension and start treatment if good BP control is not achieved. The level of BP on hypertensive encephalopathy, at least in the first 1-2 weeks after cerebral infarction. treatment is a far better predictor of stroke incidence than pre-treatment BP values.15
As almost 50% of stroke survivors will have elevated BP levels 6 months or more after the acute event, As to the optimal BP level on treatment to reduce stroke risk in hypertensives the recently published it is not surprising that anti-hypertensive treatment in the post-stroke period is frequently advocated.26 Hypertension Optimal Treatment (HOT) study suggests the lowest risk is achieved at a SBP of 140-Although raised BP levels are a strong risk factor for primary stroke, the relation with stroke recurrence is 145 mmHg and a DBP of ∏80 mmHg.16 What most studies have failed to do is to assess the effects of nowhere near as clear. Meissner et al.27 in one of the biggest studies to date found BP control was unretreatment on the different stroke subtypes, and it is unlikely that all will benefit to the same degree from lated to accumulative stroke recurrence rates over a 10-year follow-up period. Other workers have found BP lowering.
Casual BP levels are elevated during the first 24 h hypertension post stroke a risk factor, with recurrence rates in hypertensives of 16% over 2 years compared post ictus (over 80% of acute stroke patients will have a BP >160/90 during initial post stroke phase) and with 12% in normotensives.28 More recently, Rogers et al.,29 using data from the UK TIA study, showed a fall spontaneously in the subsequent 10-14 days.17 Because cerebral autoregulation is impaired after the near linear relation between follow-up SBP and DBP levels and relative risk of stroke, a 5 mmHg lowering acute event, cerebral blood flow is very sensitive to changes in systemic BP levels. It might be reasoned of DBP theoretically being associated with a 30% reduction in stroke recurrence, although the BP range that initially high values after cerebral infarction would be of benefit in terms of increasing blood flow was narrow at 130-160/80-90 mmHg. A metaanalysis of studies reporting the relation between to the ischaemic penumbra. Conversely, sustained rises could be detrimental by increasing the risk of stroke recurrence and post-stroke BP levels has suggested that raised SBP and DBP levels were associcerebral oedema and the possibility of haemorrhagic transformation of the infarct. The mechanisms underated with a RR of stroke recurrence of about 1.7, though the analysis was limited by the number of lying the rise in BP post stroke are probably due to a combination of many factors including impairment negative studies which did not report actual rates (Manktelow and Potter, unpublished data). To date, of baroreceptor sensitivity,18 increased sympathetic nervous system activity,19 activation of the renin there have been only two randomized intervention studies of the treatment of hypertension post aldosterone mechanisms, the Cushing reflex and importantly, the alerting response to BP measurement stroke,30,31 and three further studies that have involved both normotensives and hypertensive TIA in these patients.20 Observational studies reporting outcome in relation to initial BP levels have been and stroke subjects.32-34 In hypertensives, non-fatal stroke recurrence was not significantly reduced by markedly at variance, some showing an improved prognosis in those with high BP levels,21 others showactive treatment, although combined fatal and nonfatal stroke events were reduced by 35% (95% CI ing the exact opposite,22 while some have shown no relation to outcome at all.23 There are many reasons 1-57%). Taking all intervention studies including normotensives and hypertensives,30-34 fatal stroke for this disparity in terms of study methodology, but a recently published large, prospective study overcame recurrence was not reduced, but total number of strokes was reduced by 23% (95% CI 10-34%) many of these problems using 24-h BP monitoring. This showed, even allowing for other known risk and all major cardiovascular events by one-fifth 
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